Aspirin inhibits MMP-9 mRNA expression and release via the PPARα/γ and COX-2/mPGES-1-mediated pathways in macrophages derived from THP-1 cells

Biomedicine and Pharmacotherapy

Volumn 64, Issue 2, 2010, Pages 118-123

  Xue, J ^a   Hua, Y N ^a   Xie, M L ^a   Gu, Z L ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

Aspirin; Cyclooxygenase; Macrophages; Matrix metalloproteinase 9; Membranebound prostaglandin E synthase 1; Peroxisome proliferator activated receptor ; Prostaglandin E2

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; FENOFIBRATE; GELATINASE B; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROSTAGLANDIN E SYNTHASE 1;

ARTICLE; CELL STRAIN; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; INCUBATION TIME; MACROPHAGE ACTIVATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CELL LINE; CYCLOOXYGENASE 2; DINOPROSTONE; GENE EXPRESSION REGULATION; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGES; MATRIX METALLOPROTEINASE 9; PPAR ALPHA; PPAR GAMMA; RECEPTOR CROSS-TALK; SIGNAL TRANSDUCTION;

EID: 77349111718     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2009.04.033     Document Type: Article

References (27)

1. Kuzuya M., Iguchi A. Role of matrix metalloproteinases in vascular remodeling. J Artheroscler Thromb 2003, 10:275-282.
2. Kong Y.Z., Yu X.Y., Tang J.J., Ouyang X.S., Huang X.R., Gunter F.R., et al. Macrophage migration inhibitory factor induces MMP-9 expression:implications for destabilization of human atherosclerotic plaques. Artherosclerosis 2005, 178:207-215.
3. Blanquart C., Barbier O., Fruchart J.C., Staels B., Glineur C. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol 2003, 85:267-273.
4. Zambon A., Gervois P., Pauletto P., Fruchart J.C., Staels B. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-α activators: clinical and experimental evidence. Arterioscler Thromb Vasc Biol 2006, 26:977-986.
5. Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., Evans R.M. PPAR γ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998, 93:241-252.
6. Ricote M., Huang J., Fajas L., Li A., Welch J., Najib J., et al. Expression of the peroxisome proliferator-activated receptor γ (PPAR γ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1998, 95:7614-7619.
7. Ricote M., Huang J., Fajas L., Li A., Welch J., Najib J., et al. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000, 101:2411-2417.
8. Shu H., Wong B., Zhou G., Li Y., Berger J., Woods J.W., et al. Activation of PPAR α or γ reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem Biophys Res Commun 2000, 267:345-349.
9. Escher P., Braissant O., Basu-Modak S., Michalik L., Wahli W., Desvergne B. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 2001, 142:4195-4202.
10. Feige J.N., Gelman L., Michalik L., Desvergne B., Wahli W. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 2006, 45:120-159.
11. 2-dependent plaque instability. Circulation 2001, 104:921-927.
12. Mezzetti A. Pharmacological modulation of plaque instability. Lupus 2005, 14:769-772.
13. Kang Y.J., Mbonye U.R., DeLong C.J., Wada M., Smith W.L. Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation. Prog Lipid Res 2007, 46:108-125.
14. Prevention of death, myocardial infarction and stroke by antiplatelet therapy: collaborative metaanalysis of 266 trials involving 20 000 patients at high risk of occlusive vascular events. Br Med J 2002, 324:71-86. Antiplatelet Trialists Collaboration.
15. Lehmann J.M., Lenhard J.M., Oliver B.B., Ringold G.M., Kliewer S.A. Peroxisome proleferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997, 272:3406-3410.
16. Fidaleo M., Berardi E., Sartori C. Differential modulation of PPAR α and γ target gene expression in the liver and kidney of rats treated with aspirin. Exp Toxicol Pathol 2008, 59:391-397.
17. Vinals M., Bermudez I., Llaverias G., Alegret M., Sanchez R.M., Vazquez-Carrera M., et al. Aspirin increases CD36, SR-BI, and ABCA1 expression in human THP-1 macrophages. Cardiovasc Res 2005, 66:141-149.
18. Tancevski A., Wehinger W., Schgoer P., Eller B., Foeger J.R., Patsch A. Influence of aspirin on expression and function of scavenger receptor-BI within primary human macrophages: A new atheroprotective mechanism of aspirin?. Atherosclerosis 2005, 6 (Suppl.):98.
19. Karna E., Palka J.A. Inhibitory effect of acetylsalicylic acid on metalloproteinase activity in human lung adenocarcinoma at different stages of differentiation. Eur J Pharmacol 2002, 443:1-6.
20. Mehta J.L., Chen J., Yu F., Li D.Y. Aspirin inhibits ox-LDL-mediated LOX-1 expression and metalloproteinase-1 in human coronary endothelial cells. Cardiovasc Res 2004, 64:243-249.
21. Xue J., Hua Y.N., Gu Z.L., Wu K.Y., Xie M.L. Study of aspirin on inhibiting the atherosclerotic plaque rupture and MMP-2 expression of abdominal aorta in atherosclerotic rabbits. Chin Pharmacol Bull 2008, 24:1335-1339. [in Chinese].
22. Chinetti G., Griglio S., Antonucci M., Torra I.P., Delerive P., Majd Z., et al. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998, 273:25573-25580.
23. Galis Z.S., Sukhova G.K., Lark M.W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994, 94:2493-2503.
24. Hua Y.N., Xue J., Sun F., Zhu L.J., Xie M.L. Aspirin inhibits MMP-2 and MMP-9 expressions and activities through upregulation of PPARα/γ and TIMP gene expressions in ox-LDL-stimulated macrophages derived from human monocytes. Pharmacology 2009, 83:18-25.
25. Leonardo A.M., Laura P., David B.B. Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther 2006, 110:371-385.
26. Saranette C., Hassan A., Johanne M.P., Pelletier J.P., Li X.F., Katherine F., et al. Activation of peroxisome proliferator-activated receptor γ inhibits interleukin-1β-induced membrane-associated prostaglandin E2 synthase-1 expression in human synovial fibroblasts by interfering with Egr-1. J Biol Chem 2004, 279:22057-22065.
27. Gomez-Hernondez A., Martín-Ventura J.L., Sánchez-Galán E., Vidal C., Ortego M., Blanco-Colio L.M., et al. Overexpression of COX-2, prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-κB. Atherosclerosis 2006, 187:139-149.